Edition:
United States

Sanofi SA (SASY.BE)

SASY.BE on Berlin Stock Exchange

74.63EUR
7:24am EST
Change (% chg)

€1.01 (+1.37%)
Prev Close
€73.62
Open
€73.75
Day's High
€74.63
Day's Low
€73.75
Volume
13
Avg. Vol
3,439
52-wk High
€92.65
52-wk Low
€67.00

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €92,903.52
Shares Outstanding(Mil.): 1,263.13
Dividend: 2.96
Yield (%): 4.02

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA)

* ALNYLAM AND SANOFI SUBMIT MARKETING AUTHORISATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

9:49am EST

BRIEF-‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran

* Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

7:10am EST

BRIEF-Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents

* MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS

Dec 14 2017

France's Sanofi pins hopes on new drugs after setbacks

PARIS Sanofi's promising pipeline of experimental drugs can help it overcome setbacks including the low uptake of a new cholesterol treatment and concerns about a dengue vaccine, the French pharmaceuticals group said on Wednesday.

Dec 13 2017

UPDATE 4-France's Sanofi pins hopes on new drugs after setbacks

* CEO says company on track to sell European generics unit (Adds CEO comments, details, updates shares)

Dec 13 2017

Sanofi CEO says M&A targets in oncology are 'very expensive'

PARIS Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

Dec 13 2017

Sanofi CEO says M&A targets in oncology are "very expensive"

PARIS, Dec 13 Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

Dec 13 2017

Sanofi sees 9 regulatory submissions over next 18 months

PARIS, Dec 13 Sanofi said on Wednesday it saw its pipeline of new drugs supporting growth in the long term, and plans to file 9 regulatory applications over the next 18 months.

Dec 13 2017

BRIEF-Regeneron And Sanofi Announce Positive Topline Pivotal Results For Pd-1 Antibody Cemiplimab In Advanced Cutaneous Squamous Cell Carcinoma

* REGENERON AND SANOFI ANNOUNCE POSITIVE TOPLINE PIVOTAL RESULTS FOR PD-1 ANTIBODY CEMIPLIMAB IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

Dec 13 2017

Sanofi investors hungry for drug progress and deal news

PARIS, Dec 12 Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.

Dec 12 2017

Earnings vs. Estimates